Compare HOUR & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOUR | ATNM |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.8M | 36.8M |
| IPO Year | 2021 | 2013 |
| Metric | HOUR | ATNM |
|---|---|---|
| Price | $1.91 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 10.9K | ★ 104.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.57 | 30.60 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $138,252,861.00 | $81,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.14 | ★ N/A |
| Revenue Growth | ★ 4.64 | N/A |
| 52 Week Low | $1.10 | $1.02 |
| 52 Week High | $6.84 | $1.95 |
| Indicator | HOUR | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 43.37 |
| Support Level | $1.75 | $1.02 |
| Resistance Level | $1.95 | $1.25 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 35.03 | 38.74 |
Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The Company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.